secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001815776-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025
--------------------------------------------------------------------------------

- FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.
- Cash, cash equivalents & marketable securities $209.1M; cash runway expected to post-launch positive operating cash flow.
- FY2024 net loss $49.8M ($2.34/share) vs FY2023 net loss $70.0M ($35.71/share).
- R&D expenses fell to $29.8M in FY2024 from $59.5M in FY2023 as Phase 3 CLARITY study concluded.
- SG&A expenses rose to $28.8M in FY2024 from $12.9M in FY2023 due to pre-commercial buildout for potential LNZ100 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/0001815776-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/lenz-20250319.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer